A Phase I Dose Defining Study For MK-2206 Combined With Gefitinib In NSCLC Population Enriched With EGFR Mutation.

Trial Profile

A Phase I Dose Defining Study For MK-2206 Combined With Gefitinib In NSCLC Population Enriched With EGFR Mutation.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Mar 2015

At a glance

  • Drugs MK 2206 (Primary) ; Gefitinib
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 26 Dec 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 15 Nov 2012 Planned end date changed from 1 Dec 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.
    • 26 Nov 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top